Cellmid appoints Dr Bryce Vissel as chairman of scientific advisory ...
http://www.proactiveinvestors.com.au/companies/news/63324/cellmid-appoints-dr-bryce-vissel-as-chairman-of-scientific-advisory-board-63324.html

cellmid limited ( asx:cdy ) has appointed award winning researcher dr bryce vissel as chairman of its scientific advisory board to guide efforts to translate its robust science into meaningful patient outcomes .  vissel is currently the head of the neurodegenerative diseases research group at the garvan institute of medical research .  he is also conjoint senior lecturer at st vincent 's clinical school , faculty of medicine , university of new south wales .  prior to that dr vissel worked for a decade at the highly prestigious salk institute in la jolla , california , the world 's leading neuroscience laboratory .  he was recruited by the garvan institute to australia from california 's salk institute to establish and lead research in brain and spinal cord disorders and repair .  dr vissel 's research has been widely recognised internationally , and he has received a number of awards , including the prestigious fulbright award , a liebermann award and a biofirst award .  he has published more than 50 peer-reviewed papers , many in top tier journals .  maria dr vissel is a world-class researcher and his outstanding medical research experience will be invaluable in guiding cellmid 's therapeutic development programs toward clinical success .  dr vissel added :  " cellmid 's sharp focus on midkine underpins a range of therapeutic development programs for the company . this is because manipulating midkine therapeutically offers important potential for treating a range of diseases .  " my goal is to help realise this potential so that patients can benefit from the robust science underlying the company 's drug development programs . "  last month , the company was issued a notice of allowance for a u.s. patent covering its lead humanised antibody cab102 for the treatment of cancer .  this follows on patents already in force in europe , australia and japan .  its patent portfolio currently includes 88 patents in 21 patent families , which cover use of mk and anti-mk agents for therapeutic purposes in a number of diseases , as well as the use of mk as a diagnostic marker in cancer and other disorders .  proactive investors australia is the market asx emerging companies with distribution in australia , uk , north america and hong kong / china .